During our follow-up, neither the anti-BP180/BP230 positive stroke patients nor the controls exhibited BP-like skin lesions, in accordance with a previous study that showed none of the anti-BP180/BP230 antibody positive individuals had BP-like skin lesions (14). This evidence concerns the gene COL17A1 and Stroke.